Advanced search    

Search: authors:"Roy Fleischmann"

13 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

Alabama at Birmingham. Roy Fleischmann has received consultancies, speaking fees, and honoraria from AbbVie, Amgen, BMS, GSK, Janssen, Lilly, Novartis, Pfizer Inc, Sanofi-Aventis, and UCB. Ryan DeMasi is an

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis

company. Roy Fleischmann has received research grants from AbbVie, Amgen, Ardea, AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Pfizer, Roche, Sanofi, and UCB; and

Living with Psoriatic Arthritis: A Patient’s and Physician’s Perspective

This article, co-authored by a psoriatic arthritis (PsA) patient and a physician who regularly encounters and treats PsA patients, discusses the patient’s experience of living with the disease, from diagnosis through living with the disease day-to-day and other people’s reactions to their treatment experiences and responses. The physician adds to this by providing his experiences...

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients

Pharma. Disclosures. Roy Fleischmann: Research grants from Genetech Inc., Roche, Abbott, Amgen, UCB Pharma, Pfizer, BMS, Lilly, Sanofi-Aventis, MSD, Novartis, AstraZeneca and Janssen; Consultant for

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis

. Anne Paccaly is an employee of Regeneron Pharmaceuticals, Inc. and may hold stock and/or stock options in the company. Roy Fleischmann has received research grants from AbbVie, Amgen, Ardea, AstraZeneca

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs. Patients were randomized 4:3:4 to MTX administered...

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Method In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR) were randomized 4:4:1:1 to receive: tofacitinib 5 mg BID or tofacitinib 10 mg BID for the duration of the study, or...

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

Introduction The effect of certolizumab pegol (CZP) on patient-reported outcomes (PROs) was investigated in 1063 patients with rheumatoid arthritis (RA) from the REALISTIC trial (double-blind, placebo-controlled to week 12, open-label to week 28; randomized 4:1 [CZP:placebo]). Correlations between PROs and RA signs and symptoms, and the relative efficacy of these measures, were...

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Introduction This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse population of rheumatoid arthritis (RA) patients, stratified by prior anti-TNF exposure, concomitant methotrexate (MTX) use and disease duration. The ability to predict achievement of low disease activity (LDA) at week 28 from improvements in Disease...

The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life

and the impact on quality of life Roy Fleischmann 0 0 Metroplex Clinical Research Center , Dallas, Texas , USA Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of

Does safety make a difference in selecting the right TNF antagonist?

Roy Fleischmann ) 1 David Yocum 0 0 University of Arizona Arthritis Center , Tucson, AZ , USA 1 University of Texas Southwestern Medical Center , Dallas, TX , USA Tumor necrosis factor (TNF

Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and...